ライフサイエンスコーパス: IGF-binding protein 3

1 analyzed for leptin, adiponectin, IGF1, and IGF binding protein 3.

2 IGF-II (Ptrend=0.006 for both) but not with IGF binding protein-3.

3 Similar associations were observed for IGF binding protein-3.

4 n, insulin-like growth factor-I (IGF-I), and IGF binding protein-3.

5 proteins insulin-like growth factor (IGF) 1, IGF binding protein-3 and acid-labile subunit, along wit

6 r risk factors, including circulating IGF-I, IGF binding protein-3, and C-peptide.

7 r insulin, glucose, total IGF-I, free IGF-I, IGF binding protein-3, and estradiol.

8 nation of the specificity and sensitivity of IGF-binding protein-3 as an index of nutrition or anabol

9 Concomitant administration of IGF binding protein-3 blocked IGF-1-positive inotropic a

10 iously diminished muscle levels of IGF-1 and IGF binding protein 3 both increased following PRT (P <

11 Suppression of IGF binding protein-3 by palmitate promotes hepatic infl

12 on into the study and was analyzed for serum IGF-binding protein-3 concentration (by radioimmunoassay

13 IGF-binding protein-3 concentration at the time of admis

14 Variability in IGF-binding protein-3 concentration could not be explain

15 y should be considered when evaluating serum IGF-binding protein-3 concentrations as a marker of nutr

16 F-1 concentrations changed coordinately with IGF-binding protein-3 concentrations in females and male

17 s of the present study were to measure serum IGF-binding protein-3 concentrations in trauma patients

18 y must be considered when interpreting serum IGF-binding protein-3 concentrations in trauma patients.

19 In women, serum IGF-binding protein-3 concentrations were increased with

20 der were not significant predictors of serum IGF-binding protein-3 concentrations when all patients w

21 on insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 gene expression.

22 evels of insulin-like growth factor (IGF)-1, IGF binding protein-3, growth hormone (GH), and somatost

23 ed, as were hematocrit (Hct), Ep, IGF-1, and IGF-binding protein 3 (IGF-BP3) levels.

24 ternary complex formed by the association of IGF binding protein 3-IGF complexes with a serum protein

25 ALS retains the IGF binding protein-3-IGF complexes in the vascular comp

26 Plasma IGF-I and IGF binding protein 3 (IGFBP-3) concentrations and molar

27 Plasma concentrations of IGF-I and IGF binding protein 3 (IGFBP-3) were measured in blood s

28 150-kDa complex including the IGF molecule, IGF binding protein 3 (IGFBP-3), and the acid labile sub

29 erum IGF-I, IGF binding protein 1 (IGFBP-1), IGF binding protein 3 (IGFBP-3), and the IGF-I:IGFBP-3 m

30 F-I) concentrations, frequently adjusted for IGF binding protein 3 (IGFBP-3), have been associated wi

31 to direct expression of rat IGF-I and human IGF binding protein-3 (IGFBP-3) to mammary tissue during

32 thors assessed the associations of IGF-1 and IGF binding protein-3 (IGFBP-3) with cardiovascular dise

33 However, des(1-3)IGF-I, which weakly binds IGF binding protein-3 (IGFBP-3), induced IGF-IR phosphor

34 Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) is known to block IGF a

35 Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) promotes apoptosis of c

36 Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) can stimulate apoptosis

37 ix et al. demonstrate that downregulation of IGF-binding protein 3 (IGFBP-3) and -4, the negative reg

38 led that GR cells exhibited markedly reduced IGF-binding protein 3 (IGFBP-3) and IGFBP-4 RNA.

39 pproximately 13-fold (P < 0.001) increase in IGF-binding protein 3 (IGFBP-3) protein levels were also

40 like growth factor (IGF-I) content and IGF-I:IGF-binding protein 3 (IGFBP-3) ratio as risk factors fo

41 complexes with acid-labile subunit (ALS) and IGF-binding protein 3 (IGFBP-3) to maintain its circulat

42 owth factor I (IGF-I) and/or lower levels of IGF-binding protein 3 (IGFBP-3).

43 This article presents IGF-binding protein-3 (IGFBP-3) as a new modulator of ap

44 IGF-binding protein-3 (IGFBP-3) influences IGF action di

45 IGF-binding protein-3 (IGFBP-3) is a liver-derived, anti

46 IGF-binding protein-3 (IGFBP-3) is the major carrier for

47 Serum IGF-binding protein-3 (IGFBP-3) was significantly lower

48 Subsequently, IGF-1- and IGF-binding protein-3 (IGFBP-3) were analyzed using enzy

49 Notably, injection of IGF-1 plus IGF binding protein 3 (IGFBP3), but not injection of IGF

50 n assessment using Western blot analysis for IGF binding protein 3 (IGFBP3), IGF-1 receptor (IGF-1R),

51 ed and validated insulin-like growth factor (IGF)-binding protein-3 (IGFBP3) as a novel miR-21 target

52 een insulin-like growth factor 1 (IGF-1) and IGF-binding protein 3 (IGFBP3) so that the free form of

53 IGF-binding protein-3 (IGFBP3) is a member of the IGFBP

54 1 signaling by ablating IGF-1 and increasing IGF-binding protein 3, increased vSMC apoptosis, and dec

55 rmone, insulin-like growth factor-I (IGF-1), IGF binding protein-3, insulin, cortisol, parathyroid ho

56 cose, insulin, insulin-like growth factor-I, IGF binding protein-3, leptin, or body weight gain.

57 ding protein-2 levels, a slight reduction in IGF binding protein-3 levels, and an increase in levels

58 1% decrease at 1 and 2 wk, respectively) and IGF binding protein-3 levels, and increased IGF binding

59 F-I) and the concentration ratio of IGF-I to IGF binding protein 3 were lower in the low-protein, low

60 cal illness, but there is little research on IGF-binding protein-3, which regulates the bioactivity o